ClinicalTrials.gg
TerminatedNCT03362593Updated Aug 31, 2020

A 6-Part Study In Healthy Volunteers To Evaluate Safety, Tolerability and Uptake Of MEDI7219 in the Body When Given as Single and Multiple Doses

A Phase 1 interventional study of MEDI7219 and Placebo in Healthy Volunteers, sponsored by MedImmune LLC. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-31.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Why this study was terminated
The program is canceled due to company strategic reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a 6-part study to evaluate the safety, tolerability, and PK of MEDI7219 in healthy subjects. Parts A, B, C \& E are the single-dose parts of the study. Parts D \& F are the multiple ascending dose (MAD) parts of the study. The starting dose and formulation for Parts D \& F will be selected from data emerging from Parts A, B and E. Enrollment of approximately 198 subjects is anticipated.

Read the detailed description

MEDI7219 is being developed for the potential treatment of type 2 diabetes. The study is a first in human, single and multiple ascending dose study that will try to identify the safety, tolerability and pharmacokinetics (how the drug moves through the body) of MEDI7219. The study will also look at the impact of changes to the formulation as well as differences related to the route of administration. The study will consist of 6 parts involving approximately 198 healthy male and female subjects (and up to 146 additional subjects). In Part A, 6 cohorts of 10 subjects each (with an optional 2 cohorts) will be randomized to receive MEDI7219 or one of two placebos. Each cohort will receive a different formulation of the study drug. In part B, a single cohort of 16 subjects (with an optional second cohort) will receive a different formulation of MEDI7219 per period in up to 5 periods. In Part C, up to 12 subjects will be dosed with MEDI7219. In Part D, one cohort of 30 subjects (with an optional second cohort) will be randomized to receive MEDI7219 or placebo. Subjects will start on a dose based on data from previous parts and will receive ascending doses for 35 days. In Part E, 2 cohorts of 6 subjects each (with an optional third \& fourth cohort of 12 subjects each) will receive a different formulation of MEDI7219 per period. Part E, cohort 5 12 subjects each period (2 periods) has been added to assess 2 different formulations In Part F, two cohorts of 16 subjects each will be randomized to receive MEDI7219 or placebo. Subjects will start on a dose based on data from previous parts and will receive ascending doses for 35 days.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.

Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.

First submitted after MedImmune LLC became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers age 18-55 years
  • 18-32 kg/m2
  • Females not of
  • Able and willing to adhere to the protocol
  • Must provide written

Exclusion criteria

Exclusion Criteria:

  • Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the product
  • Abnormal lab values, physical exam, vital signs
  • Positive drug or alcohol screen.
  • Current enrollment in another clinical study or enrollment within the past 3 months
  • Any illness, medical/surgical procedure, or trauma within 4 weeks prior to dosing
  • Abnormal
  • Positive , or test
  • Positive Drug or Alcohol screen
  • Current smokers or those who have smoked within the last 12 months
  • Recent plasma or blood donation
  • Evidence of current SARS-CoV-2 infection (Part E Cohort 5 and Part F Cohort 2 only)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
186 participants (actual)

Study arms

  • Experimental
    MEDI7219

    Experimental Drug

    Drug: MEDI7219

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Placebo comparator
    Formulation without Active Drug

    Formulation without Active Drug

    Drug: Formulation without Active Drug

Interventions

  • DrugMEDI7219

    Experimental Drug

  • DrugPlacebo

    Placebo

  • DrugFormulation without Active Drug

    Formulation without Active Drug

06

What researchers measure

Primary outcomes

  1. Number of subjects with Adverse Events as a measure of safety and tolerability of MEDI7219

    Treatment emergent adverse events (TEAEs) and serious adverse events (TESAEs)

    Time frame: Baseline to last follow up visit (Parts A and C - Day 28) (Part D & F Day 63) and (Parts B and E 28 days post last dose)

Secondary outcomes

  1. Pharmacokinetics of MEDI7219: Cmax

    PK parameters will be calculated from the plasma concentration versus time data for Cmax (maximum observed concentration)

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Parts D & F pre-dose to Day 63/EOS visit

  2. Pharmacokinetics of MEDI7219: Tmax

    PK parameters will be calculated from the plasma concentration versus time data for Tmax (time to maximum observed concentration)

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Parts D & F pre-dose to Day 63/EOS visit, Parts F cohort 2 ONLY: Pre-dose and 8 hours post-dose

  3. Pharmacokinetics of MEDI7219: t1/2

    PK parameters will be calculated from the plasma concentration versus time data for T1/2 (terminal half-life)

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Parts D & F pre-dose to Day 63/EOS visit

  4. Pharmacokinetics of MEDI7219: AUC (0-inf)

    PK parameters will be calculated from the plasma concentration versus time data for AUC (0-inf) \[area under the curve (AUC) extrapolated to infinity\]

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Parts D & F pre-dose to Day 63/EOS visit

  5. Pharmacokinetics of MEDI7219: AUC(0-last)

    PK parameters will be calculated from the plasma concentration versus time data for AUC (0-last) \[area under the curve (AUC) from time 0 to last measurable concentration\]

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Parts D & F pre-dose to Day 63/EOS visit

  6. Pharmacokinetics of MEDI7219: AUC(0-24h)

    PK parameters will be calculated from the plasma concentration versus time data for (AUC 0-24) \[area under the curve (AUC) from time 0 to 24 hours post dose\]

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Parts D & F pre-dose to Day 63/EOS visit

  7. Pharmacokinetics of MEDI7219: AUC (%extrap)

    PK parameters will be calculated from the plasma concentration versus time data for AUC%extrapolated \[The percentage of AUC(0-inf) accounted for by extrapolation\]

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only)

  8. Pharmacokinetics of MEDI7219: Lambda-z

    PK parameters will be calculated from the plasma concentration versus time data for Lambda-z \[Slope of the regression line passing through the apparent elimination phase in a concentration vs time plot\]

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B, C and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only)

  9. Pharmacokinetics of MEDI7219: CL/F

    PK parameters will be calculated from the plasma concentration for CL/F (apparent clearance)

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only)

  10. Pharmacokinetics of MEDI7219: Vz/F

    PK parameters will be calculated from the plasma concentration for Vz/F (volume of distribution)

    Time frame: Pre-dose to 144 hours post-dose (Parts A, B and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only); Pre-dose to Day 63/EOS visit (Parts D & F)

  11. Pharmacokinetics of MEDI7219: Frel

    PK parameters will be calculated from the plasma concentration for Frel (relative bioavailability)

    Time frame: Pre-dose to 144 hours post-dose (Parts B and Part E cohorts 1 & 2 only); Pre-dose to 168 hours post-dose (Part E optional cohorts only)

  12. Pharmacokinetics of MEDI7219: Vd

    PK parameters will be calculated from the plasma concentration for Vd (volume of distribution)

    Time frame: Pre-dose to 144 hours (Part C)

  13. Pharmacokinetics of MEDI7219: F

    PK parameters will be calculated from the plasma concentration for F (absolute bioavailability)

    Time frame: Pre-dose to 144 hours (Part C )

  14. Pharmacokinetics of MEDI7219: AUC (0-tau)

    PK parameters will be calculated from the plasma concentration versus time data for AUC (0-tau) \[area under the curve (AUC) for a dosing interval\]

    Time frame: Pre-dose to Day 63/EOS visit (Parts D & F)

  15. Immunogenicity

    Presence of Anti-drug antibody to MEDI7219

    Time frame: Day -1 to Day 28/EOS Visit (Parts A and C); Day -1 to Day 63/EOS Visit (Parts D & F); Day -1 to 28 days post last dose of final period/EOS Visit (Parts B and E)

  16. Pharmacokinetics of Formulation Component: Cmax

    PK parameters will be calculated from the plasma concentration versus time data for Cmax (maximum observed concentration)

    Time frame: Predose to 8 hours post dose Day 1 (Parts A, B and E); Pre-dose to 8 hours post dose on Days 1, 7, 8, 14, 15, 21, 22, 28, 29 and 35 (Part D and F Cohort 1); Pre-dose to 24 hours post dose on Days 1, 14, 28 and 35 (Part F Cohort 2, respectively)

  17. Pharmacokinetics of Formulation Component: Tmax

    PK parameters will be calculated from the plasma concentration versus time data for Tmax (time to maximum observed concentration)

    Time frame: Predose to 8 hours post dose Day 1 (Parts A, B and E); Pre-dose to 8 hours post dose on Days 1, 7, 8, 14, 15, 21, 22, 28, 29 and 35 (Part D and F Cohort 1); Pre-dose to 24 hours post dose on Days 1, 14, 28 and 35 (Part F Cohort 2, respectively)

  18. Pharmacokinetics of Formulation Component: T(1/2)

    PK parameters will be calculated from the plasma concentration versus time data for T1/2 (terminal half-life)

    Time frame: Predose to 8 hours post dose Day 1 (Parts A, B and E); Pre-dose to 8 hours post dose on Days 1, 7, 8, 14, 15, 21, 22, 28, 29 and 35 (Part D and F Cohort 1); Pre-dose to 24 hours post dose on Days 1, 14, 28 and 35 (Part F Cohort 2, respectively)

  19. Pharmacokinetics of Formulation Component: AUC (0-inf)

    PK parameters will be calculated from the plasma concentration versus time data for AUC (0-inf) \[area under the curve (AUC) extrapolated to infinity\]

    Time frame: Predose to 8 hours post dose Day 1 (Parts A, B and E); Pre-dose to 8 hours post dose on Days 1, 7, 8, 14, 15, 21, 22, 28, 29 and 35 (Part D and F Cohort 1); Pre-dose to 24 hours post dose on Days 1, 14, 28 and 35 (Part F Cohort 2, respectively)

  20. Pharmacokinetics of Formulation Component: AUC (0-last)

    PK parameters will be calculated from the plasma concentration versus time data for AUC (0-last) \[area under the curve (AUC) from time 0 to last measurable concentration\]

    Time frame: Predose to 8 hours post dose Day 1 (Parts A, B and E); Pre-dose to 8 hours post dose on Days 1, 7, 8, 14, 15, 21, 22, 28, 29 and 35 (Part D and F Cohort 1); Pre-dose to 24 hours post dose on Days 1, 14, 28 and 35 (Part F Cohort 2, respectively)

  21. Pharmacokinetics of Formulation Component: AUC (0-8h)

    PK parameters will be calculated from the plasma concentration versus time data for (AUC 0-24) \[area under the curve (AUC) from time 0 to 8 hours post dose\]

    Time frame: Predose to 8 hours post dose Day 1 (Parts A, B and E); Pre-dose to 8 hours post dose on Days 1, 7, 8, 14, 15, 21, 22, 28, 29 and 35 (Part D and F Cohort 1); Pre-dose to 24 hours post dose on Days 1, 14, 28 and 35 (Part F Cohort 2, respectively)

  22. Pharmacokinetics of MEDI7219: CL

    PK parameters will be calculated from the plasma concentration from CL (apparent clearance)

    Time frame: Pre-dose to 144 hours post-dose (Part C)

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ standards.

Supporting information: Informed consent form

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in May 2020, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2017
First posted
Dec 5, 2017
StartActual
Dec 4, 2017
Primary completionActual
May 11, 2020
CompletionActual
May 11, 2020
Last update
Aug 31, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03362593
Lead sponsor
MedImmune LLC
Responsible party
Sponsor
First posted
Dec 5, 2017
Start date
Dec 4, 2017
Primary completion
May 11, 2020
Completion
May 11, 2020
Last update
Aug 31, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion